|
|
News Breaks | | | | September 4, 2012 | | 06:46 EDT |  | MDVN | Medivation price target raised to $122 from $113 at Jefferies
Jefferies raised its price target for Medivation after Xtandi won FDA approval three months earlier than expected. The firm found the drug's label in-line with expectations and reiterates a Buy rating on the stock. | |
|
News For MDVN From The Last 14 Days Check below for free stories on MDVN the last two weeks. |
|
|
| May 14, 2013 | | 14:59 EDT |  | MDVN | Medivation has a conference call hosted by JPMorgan
JPMorgan Analysts Meacham and Kasimov host a conference call with CEO David Hung on May 16 at 10 am. | | | May 9, 2013 | | 16:23 EDT |  | MDVN | Medivation sees FY13 operating expenses, net of Astellas payments, $285M-$300M
 Subscribe for More Information | | | 16:23 EDT | | MDVN | Medivation reports Q1 EPS (36c), consensus (41c)
Reports Q1 revenue $46.15M, consensus $38.54M. | | | 15:27 EDT | | MDVN | Notable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include priceline.com (PCLN), consensus $5.27; Public Storage (PSA), consensus $1.62; NVIDIA (NVDA), consensus 10c; CareFusion (CFN), consensus 53c; Assured Guaranty (AGO), consensus 68c; Medivation (MDVN), consensus (41c); Great Plains Energy (GXP), consensus 12c; Salix Pharmaceuticals (SLXP), consensus 68c; Air Lease (AL), consensus 38c; Sotheby's (BID), consensus (12c). | | | May 6, 2013 | | 09:38 EDT | | MDVN | Medivation Xtandi estimates raised at Leerink
Subscribe for More Information | |
|
|
|
|
|
|
